Dechra acquires Isoflurane and Sevoflurane Inhalant Anesthetic Products from Halocarbon Life Sciences
The veterinary pharmaceutical company adds 2 key products to its companion animal offerings.
Dechra Pharmaceuticals has acquired Isoflurane USP Inhalant Anesthetic and Sevoflurane USP Inhalant Anesthetic from Halocarbon Life Sciences.1 The 2 inhalation anesthesia solutions are used in both human and animal medicine.2 Dechra plans to launch veterinary branded Isoflurane and Sevoflurane products this year.
“These products are utilized daily in veterinary hospitals and complement our current sedative and anesthetic product range,” said Mike Eldred, President of Dechra North America. “We are excited to continue to grow and expand our veterinary surgical suite and anesthetic portfolio and offer high quality products to the veterinary community.”
The rollout for Dechra’s veterinary branded Isoflurane and Sevoflurane is scheduled for the first quarter of 2022. Isoflurane and Sevoflurane come as an addition to Dechra’s pharmaceutical companion animal portfolio Dechra’s companion animal portfolio, focusing on endocrinology, dermatology, ophthalmology, anesthesia, fluid therapy, pain management, joint health support, and dental care.1
Halocarbon Life Sciences is a leading global supplier of Isoflurane and Sevoflurane inhalation anesthetic products for human and veterinary healthcare. The company works toward the research and development of fluorochemical technologies and manufacturing processes in the life science space.2
- Dechra acquires Isoflurane and Sevoflurane from Halocarbon Life Sciences. Dechra. January 7, 2022. Accessed January 10, 2022. https://www.dechra-us.com/news/2022/january/dechra-acquires-isoflurane-and-sevoflurane-from-halocarbon-life-sciences
- Halocarbon Life Sciences. Accessed January 10, 2022. https://halocarbon-ls.com/